Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

@article{Dismukes1987TreatmentOC,
  title={Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.},
  author={W. Dismukes and G. Cloud and H. Gallis and T. Kerkering and G. Medoff and P. Craven and L. Kaplowitz and J. Fisher and C. Gregg and C. Bowles and S. Shadomy and A. Stamm and R. Diasio and L. Kaufman and S. Soong and W. Blackwelder},
  journal={The New England journal of medicine},
  year={1987},
  volume={317 6},
  pages={
          334-41
        }
}
One hundred ninety-four patients with cryptococcal meningitis were enrolled in a multicenter, prospective, randomized clinical trial to compare the efficacy and toxicity of four as compared with six weeks of combination amphotericin B and flucytosine therapy. Among 91 patients who met preestablished criteria for randomization, cure or improvement was noted in 75 percent of those treated for four weeks and in 85 percent of those treated for six weeks. The estimated relapse rate for the four-week… Expand
Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.
TLDR
Amphotericin B used in combination with flucytosine has superior mycologic and clinical efficacy compared with fluconazole for the treatment of cryptococcal meningitis in patients with AIDS. Expand
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.
TLDR
Am amphotericin B-induced azotemia was not a significant risk factor for the subsequent development of bone marrow, gastrointestinal, or hepatic toxicity attributable to flucytosine in patients with cryptococcal meningitis. Expand
Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.
TLDR
The results appear sufficiently encouraging to warrant further trials of this oral agent in the suppression of chronic cryptococcosis and perhaps in the treatment of acute infection. Expand
Parenteral and Oral Fluconazole for Acute Cryptococcal Meningitis in Aids: Experience with Thirteen Patients
TLDR
In this small group of patients, moderate doses of parenteral and oral fluconazole for acute cryptococcal meningitis in AIDS patients demonstrated failure rates similar to those reported in other studies with flu Conazole and with amphotericin B. Expand
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
TLDR
Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS and single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. Expand
Flucytosine monotherapy for cryptococcosis.
  • D. Hospenthal, J. Bennett
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
TLDR
Although the 57% failure rate associated with 5-FC alone precludes its use as monotherapy, this study did show that this treatment was well tolerated and that failure was not invariably associated with development of resistance. Expand
Comparison of Amphotericin B and its combination with Flucytosine in the Management of Cryptococcal Meningitis: a Review
TLDR
Evidence was found that combining Amphotericin B with Flucytosine had better clinal improvement than AmB monotherapy, and in all studies included FlucyTosine addition resulted better outcomes in cerebrospinal fluid yeast count, serologic evidence, clinical symptoms, survival rate, or occurrence of adverse drug events. Expand
Oral Itraconazole Therapy of Cryptococcal Meningitis and Cryptococcosis in Patients with AIDS
TLDR
Oral itraconazole is promising for the primary or salvage therapy of cryptococcal meningitis and other forms of cryptococcosis in patients with AIDS and response rates compare favorably to amphotericin B therapy with or without flucytosine. Expand
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis
TLDR
Quantitative determinations of CFU in brain tissue demonstrated a significantly lower burden of C. neoformans in mice receiving combined therapy, indicating that combined therapy with fluconazole and flucytosine is superior to single-drug therapy. Expand
Therapy for cryptococcal meningitis in patients with AIDS.
  • W. Powderly
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1992
TLDR
Fluconazole is highly effective in suppressing relapses of cryptococcal meningitis and Itraconazole has been investigated less extensively in the treatment of cryptococcosis but offers promise. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis.
TLDR
It is concluded that combined flucytosine-amphoericin B therapy is the regimen of choice in cryptococcal meningitis. Expand
Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.
TLDR
It is suggested that maintenance therapy with amphotericin B may be needed to prevent relapse in patients with AIDS. Expand
Cryptococcosis in the acquired immunodeficiency syndrome.
TLDR
Cryptococcosis in patients with the acquired immunodeficiency syndrome is a debilitating disease that does not respond to conventional therapy; earlier diagnosis or long-term suppressive therapy may improve the prognosis. Expand
DIAGNOSTIC AND PROGNOSTIC VALUE OF CLINICAL AND LABORATORY FINDINGS IN CRYPTOCOCCAL MENINGITIS, A FOLLOW-UP STUDY OF FORTY PATIENTS.
TLDR
In the present report 40 cases of cryptococcal meningitis seen at the National Institutes of Health will be reviewed, particular attention being given to symptoms and cerebrospinal-fluid and cultural findings before treatment and the relation. Expand
Cure of cryptococcal infection during continued immunosuppressive therapy.
TLDR
The experience indicates that the prognosis for the renal transplant patient who has cryptococcosis can be improved and maintenance immunosuppressive therapy may be continued throughout the period of antifungal therapy and does not preclude eradication of the infecting organisms. Expand
Cryptococcal meningitis A review of 32 years experience
This study is a review of cryptococcal meningitis in Queensland, Australia, with particular reference to changes in incidence, methods of diagnosis and treatment and their effects on mortality andExpand
Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function.
TLDR
A linear correlation was found to exist between the elimination rate constant of the drug and creatinine clearance, and based on this, a 5-FC dosage schedule has been proposed for patients with impaired kidney function. Expand
Cryptococcal meningitis: diagnostic value of cryptococcal antigen in cerebrospinal fluid.
TLDR
In certain patients with chronic meningitis, the detection of cryptococcal antigen in the CSF may be the only means of establishing a diagnosis during life and antifungal therapy should be initiated, pending results of other diagnostic studies. Expand
Diagnosis of cryptococcal meningitis. Value of immunologic detection of cryptococcal antigen.
TLDR
In three patients with chronic meningitis and repeatedly negative cultures cryptococcal antigen was detected in the cerebrospinal fluid by the latex agglutination test, supported by complete recovery after amphotericin B therapy in two patients and demonstration of cryptococci at autopsy in the third. Expand
Intracranial infection in cardiac transplant recipients
TLDR
Of the first 182 transplant recipients, 27 developed nonviral intracranial infections: meningoencephalitis/abscess in 16 patients, meningitis in 9, and rhinocerebral phycomycoses in 2. Expand
...
1
2
...